Eurosurveillance banner


The emergence and spread of antimicrobial resistance (AMR) is a growing problem in many European countries. To mark the very first European Antibiotic Awareness Day, on 18 November, the scientific journal Eurosurveillance runs a series of articles to highlight main aspects of the AMR problem in Europe. They will be published in two issues on 13 and 20 November 2008.

In preparation for the coming influenza season 2008-9, Eurosurveillance publishes a special issue on prevention of influenza by vaccination. Seasonal influenza poses a serious public health threat because of associated serious morbidity and mortality. In Europe, estimates suggest that influenza is responsible for around 40,000 to 220,000 excess deaths, depending on the severity of the epidemic.

Today Eurosurveillance is publishing a special issue dedicated to the widespread advances made in Europe in estimating the real number of newly acquired HIV infections based on an innovative approach called STARHS

To tie in with World Hepatitis Day on 19 May, the scientific journal Eurosurveillance is today publishing a special issue on viral hepatitis, highlighting issues and challenges related to hepatitis B and C.

On 17 April 2008, Eurosurveillance is publishing a special issue with articles on the measles situation in Europe. The publication is linked to European Immunisation Week which runs from 21-27 April.

World Tuberculosis Day on 24 March commemorates the date in 1882 when Robert Koch presented his findings of the causing agent of tuberculosis (TB) – Mycobacterium tuberculosis. In the run up of this day Eurosurveillance publishes a special issue on the situation of TB in Europe.

Today (6 March, 2008), Eurosurveillance, the European peer-reviewed journal of infectious diseases, publishes a special issue on meningococcal disease. It includes two in-depth articles and an editorial by the European Centre for Disease Prevention and Control (ECDC).


In this issue


Home Eurosurveillance Monthly Release  2004: Volume 9/ Issue 11 Article 1 Printer friendly version
Back to Table of Contents
en es fr pt
Next

Eurosurveillance, Volume 9, Issue 11, 01 November 2004
Editorial
How to prevent transmission of MRSA in the open community?

Citation style for this article: Vandenesch F, Etienne J. How to prevent transmission of MRSA in the open community?. Euro Surveill. 2004;9(11):pii=483. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=483

 

Francois Vandenesch and Jerome Etienne
Centre National de Référence des Staphylocoques, Lyon, France

 



 
In the past 20 to 30 years, methicillin-resistant Staphylococcus aureus (MRSA) strains have been present in hospitals and have become a major cause of hospital-acquired infection. Methicillin resistance rates of S. aureus vary considerably between countries, with a high prevalence in the United States, and southern Europe (> 20%) and a low prevalence in northern Europe (< or = 5%). Community-acquired MRSA emerged worldwide in the late 1990s. There has been great confusion in the literature between healthcare-associated MRSA infections occurring in the community in patients who are at risk of acquiring hospital MRSA (such as those with past history of hospital admission, immunocompromised status, etc.), and true CA-MRSA infections due to strains that are present in the community only.

Demographic characteristics of hospital-acquired (HA-)MRSA infections differ from those of CA-MRSA, the former occurring mainly in elderly people and the latter occurring in young people. HA-MRSA infections are particularly associated with surgical wounds or intravenous indwelling catheters. CA-MRSA infections are mainly primary skin and soft tissue infections occurring in patients with no initial skin wounds. The Panton-Valentine leukocidin (PVL) produced by CA-MRSA strains all over the world represents, with its necrotic activity, one of the virulence factors possibly associated with cutaneous tissue destruction. The necrotic activity of PVL seems to be the major factor behind dramatic cases of necrotising pneumonia, leading to a massive alveolar septa destruction; the mortality rate is 75%.

These PVL-positive CA-MRSA are easily transmissible not only within families but also on a larger scale in community settings such as prisons, schools and sport teams. Skin-to-skin contact involving no abrasion and indirect contact with contaminated objects such as towels, sheets, sport equipment seem to represent the mode of transmission. The skin infection often has the initial appearance of an insect bite. In the US, infected prisoners were thought to have been bitten by spiders, and in our institution, a skillful technicians who had been working for several years with PVL positive CA-MRSA thought she had been bitten by a mosquito before developing a large forearm skin abscess which required surgical treatment. The exact prevalence of CA-MRSA is still unknown, as the isolated strains have mainly been taken from patients requiring admission to hospital. These isolates collected at hospitals certainly represent the tip of the iceberg of the entire population of the CA-RSA spreading in each continent. The most prevalent clone of CA-MRSA strains, assigned to the multilocus sequence type 0 (ST 80), have been detected in several European countries, demonstrating its epidemicpotential.. It has been detected in rance, Switzerland, Germany, Greece and also the Nordic countries that were initially protected rom the HA-MRSA invasion. Another clone (ST30), initially described in Australasia is reported in this issue of Eurosurveillance to have spread both in the Netherlands and in Latvia [1,2], demonstrating the intercontinental spread of this clone. Similarly the ST8 and ST59 clones, initially described in the US, have been reported in the Netherlands by Wannet et al [2]. The small-sized SCCmec type IV element uniformly present in CA-MRSA reported so far is no longer a universal feature of CA-MRSA, as Wannet et al report the presence of SCCmec type I and III in some of their strains.

Although MRSA has been described for decades in hospital settings, these strains never previously appeared to represent a threat to the community. Currently, the threat appears to be that strains that first emerged in the community will spread further within the community, and may potentially spread to hospitals too [1]. Will all S. aureus strains progressively become resistant to methicillin?

The first priority is to set up and implement adequate prevention measures to reduce or limit the spreading of these strains. In past outbreaks when cases of skin and soft tissue infections have been observed in a close-living community of patients, conventional therapeutic and infection control measures have proven successful in curing the infected patients and controlling the outbreak. The main question now is how to prevent transmission of these strains in the open community.


References

1. E. Miklaševics, S. Hæggman, A. Balode, B. Sanchez, A. Martinsons, B.Olsson-Liljequist, U. Dumpis Report on the first PVL-positive community acquired MRSA strain in Latvia. Euro Surveill 9 in press
2. WJB Wannet, MEOC Heck, GN Pluister, E Spalburg, MG van Santen, XW Huijsdens et al Panton-Valentine leukocidin positive MRSA: The Dutch situation. Euro Surveill 9 in press

 



Back to Table of Contents
en es fr pt
Next

Disclamer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the Editorial team or the institutions with which the authors are affiliated. Neither the ECDC nor any person acting on behalf of the ECDC is responsible for the use which might be made of the information in this journal.
Eurosurveillance [ISSN] - ©2008 All rights reserved